LCM
NAMS icon

Legato Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Legato Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$690K Sell
21,570
-62,263
-74% -$2.03M 0.06% 416
2025
Q4 		$2.94M Buy
83,833
+60,463
+259% +$2.2M 0.25% 90
2025
Q3 		$665K Buy
23,370
+4,581
+24% +$110K 0.07% 400
2025
Q2 		$340K Buy
+18,789
New +$343K 0.04% 489

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Legato Capital Management's NAMS Position: Q1 2026 in Review

Legato Capital Management reduced its NewAmsterdam Pharma (NAMS) stake by 74% in Q1 2026, selling an estimated $2.03M and leaving 21,570 shares worth $690K. The position accounts for 0.06% of the portfolio, ranked #416.

Legato Capital Management first reported a position in NAMS in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.94M in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Legato Capital Management held 21,570 shares of NewAmsterdam Pharma worth $690K as of Q1 2026.
  • Legato Capital Management sold 62,263 NewAmsterdam Pharma shares in Q1 2026, an estimated $2.03M.
  • NewAmsterdam Pharma made up 0.06% of Legato Capital Management's portfolio in Q1 2026, its #416 holding.
  • Legato Capital Management first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 4 quarters since.
  • Legato Capital Management's NewAmsterdam Pharma position peaked at $2.94M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.